Thermo Fisher Divests Microbiology Business to Astorg for $1.1B: Diagnostics Portfolio Optimization Continues

The Deal at a Glance

On April 27, 2026, Thermo Fisher Scientific (NYSE: TMO) announced that it had signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately $1.075 billion. The consideration consists of cash and a $50 million seller note.

The transaction is expected to close in the second half of 2026, subject to customary closing conditions and applicable regulatory approvals. Until closing, Thermo Fisher will continue to operate the business.

The deal represents one of the most significant diagnostics divestitures of 2026 and reflects an accelerating trend among large-cap life sciences companies: shedding non-core or subscale units to concentrate capital on higher-growth, higher-margin businesses.

The Microbiology Business: What Was Sold

Thermo Fisher's microbiology unit is one of five primary businesses within the company's Specialty Diagnostics segment. The business provides diagnostic consumables and equipment centered on two core product categories:

1. Antimicrobial susceptibility testing (AST) — Systems and consumables used to determine which antibiotics are effective against specific bacterial infections, guiding clinical treatment decisions.
2. Culture media solutions — Products used to grow and identify microorganisms from clinical specimens, pharmaceutical quality control samples, and food safety tests.

These products serve three end markets:

• Clinical diagnostics — Hospital and reference laboratory testing for infectious disease identification and antibiotic resistance profiling.
• Pharmaceutical quality control — Sterility testing, environmental monitoring, and microbial limits testing required under GMP manufacturing regulations.
• Food safety testing — Detection and enumeration of pathogens and spoilage organisms in food production and processing.

Business Profile at a Glance

The business sells culture media, collection and transport systems, instruments, and consumables to detect pathogens in blood, specimen tests, and quality-control products. Its product portfolio is anchored by two flagship brands — Oxoid and Remel — which are among the most recognized names in microbiology diagnostics worldwide. As Astorg partners Olivier Lieven and Paul Arhanchiague noted in the acquisition announcement: "Thermo Fisher's microbiology business, through its Remel and Oxoid brands, sits at the core of testing workflows in life sciences and plays an important role in global food safety."

The Oxoid brand, with roots dating to the 1920s, is best known for its dehydrated and prepared culture media, chromogenic media (including the Brilliance range for MRSA, E. coli, and Candida detection), blood culture systems, and diagnostic kits used across clinical, food safety, and pharmaceutical laboratories. The Remel brand, headquartered in Lenexa, Kansas, provides one of the industry's broadest catalogs of prepared culture media (over 1,700 formulations), biochemical identification systems (RapID), antimicrobial susceptibility testing products, and quality control organisms. Together, these brands cover the full microbiology workflow from specimen collection and transport through organism identification and antimicrobial susceptibility testing.

The business brings over 100 years of microbiology manufacturing heritage, with Thermo Fisher noting that its microbiology expertise traces to 1924. While growing at nearly 2% year over year, the microbiology unit's growth profile likely trails Thermo Fisher's faster-growing segments — a key factor in the strategic decision to divest.

Rumors of a potential sale first surfaced in June 2025, nearly ten months before the definitive agreement was signed. The extended timeline suggests a deliberate process to find the right buyer at the right valuation, rather than a distressed exit.

Deal Structure and Financial Details

The $1.075 billion consideration is composed of cash and a $50 million seller note. The seller note structure means Thermo Fisher retains a small financial interest in the post-close performance of the business — a mechanism commonly used in private equity carve-outs to align incentives and bridge valuation gaps.

Valuation Context

The implied revenue multiple of approximately 1.7x is modest relative to medtech M&A benchmarks, which typically range from 3x to 8x revenue for higher-growth diagnostics assets. However, for a mature, low-single-digit-growth consumables business with significant manufacturing infrastructure, this multiple reflects the market's assessment of the unit's growth and margin profile. It also reflects the carve-out nature of the transaction — the business will require investment to operate as a standalone entity, which affects valuation.

EPS Impact

Thermo Fisher disclosed that the transaction is expected to be dilutive to adjusted earnings per share by $0.15 in the first full year following close. This level of dilution is modest for a company of Thermo Fisher's scale — the company reported adjusted EPS of $22.87 in 2025 — and signals that the microbiology business, while profitable, was not a major earnings driver relative to the broader portfolio.

For context, the dilution from this divestiture is smaller in absolute terms than the earnings contribution from Thermo Fisher's recently completed $8.9 billion acquisition of Clario, which added $30 million in revenue and $0.01 in adjusted EPS to Q1 2026 results alone, according to the company's first-quarter reporting. Thermo Fisher's laboratory products and biopharma services segment posted 7% year-over-year revenue growth to $6.04 billion in Q1 2026, underscoring the stronger growth trajectories the company is prioritizing over the microbiology unit's approximately 2% growth.

Thermo Fisher stated it would provide details on the expected impact to its 2026 financial outlook during its second quarter earnings call.

Why Thermo Fisher Is Selling: Portfolio Optimization

CEO Marc N. Casper articulated the strategic rationale clearly: "The transaction reflects our active management of the company and provides additional capital we can deploy to create shareholder value."

Casper added: "We believe the microbiology business is an excellent fit within Astorg's portfolio. We are confident in a smooth transition and wish the business and colleagues continued success after close under its new ownership."

The Strategic Logic

Several factors drive Thermo Fisher's decision to divest:

1. Growth profile mismatch. The microbiology unit grew roughly 2% year over year, a rate that likely trails Thermo Fisher's portfolio average and substantially trails its higher-growth segments such as bioprocessing, gene therapy, and proteomics. For a company with Thermo Fisher's scale and ambitions, low-single-digit growth units consume management attention and capital that could be redeployed to faster-growing categories.

2. Capital reallocation. The approximately $1.025 billion in cash proceeds (net of the seller note) provides Thermo Fisher with additional firepower for acquisitions, share repurchases, or investment in higher-return segments. In a medtech M&A environment described by PwC's 2026 outlook as focused on "targeted, capability-building acquisitions," having capital available for strategic deployment is a competitive advantage.

3. Portfolio simplification. The microbiology business, while solid, is one of five primary businesses within Specialty Diagnostics — itself one of Thermo Fisher's four reporting segments. Divesting a non-core sub-unit simplifies the organizational structure and allows management to focus on segments with stronger strategic coherence.

4. Market positioning. Thermo Fisher has been pivoting its portfolio toward biopharma services, life sciences tools, and higher-margin specialty diagnostics. The Dark Report noted that Thermo Fisher's lab products and specialty diagnostics divisions constituted the world's largest in vitro diagnostics (IVD) business by revenue. Shedding the microbiology unit sharpens that positioning without fundamentally altering Thermo Fisher's scale.

Astorg's Healthcare Platform Strategy

Astorg is not a generic financial buyer making a passive investment. The firm has built one of the most focused healthcare private equity platforms in Europe, and the Thermo Fisher microbiology acquisition fits squarely within its established investment thesis.

Astorg at a Glance

Proven Healthcare Platform Builder

Astorg has assembled an impressive track record of building scaled, specialized healthcare platforms:

Notably, the Solabia platform recently acquired Xebios Group (Germany/Netherlands), a microbiological diagnostics solutions provider with capabilities in water, food and beverage, and clinical testing. This acquisition — completed just weeks before the microbiology deal announcement — broadens Solabia's microbiology diagnostics capabilities and creates a potential strategic complement to the newly acquired Thermo Fisher microbiology business, should Astorg choose to consolidate its diagnostics interests over time.

Astorg itself previously sold Clario to Thermo Fisher for $8.875 billion (approximately $8.9 billion) in a transaction completed in March 2026, alongside co-investors including Nordic Capital, Novo Holdings, and Cinven — meaning the two firms have recent, direct deal experience with each other. This familiarity likely facilitated the microbiology transaction.

Astorg's Stated Strategy for the Microbiology Business

Astorg outlined its strategic plan in its acquisition announcement:

• Operate as an independent platform — The microbiology business will become a standalone, privately owned company, not integrated into an existing Astorg portfolio company.
• Partner with management — Astorg emphasized its intention to work closely with the existing leadership team.
• Accelerate growth — Focus on organic growth initiatives and potential add-on acquisitions.
• Enhance operational performance — Invest in operational capabilities and infrastructure required for standalone operations.

Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, stated: "This investment reflects our strong conviction in microbiology diagnostics and exemplifies Astorg's approach to creative dealmaking, leveraging deep sector expertise to identify global assets, navigate complexity, and translate it into a clear, executable growth strategy."

Structural Tailwinds

Astorg identified three structural trends supporting the microbiology market:

1. Infection complexity — Rising antimicrobial resistance and increasingly complex infectious disease profiles are driving demand for more sophisticated susceptibility testing.
2. Food safety standards — Regulatory requirements for food safety testing continue to tighten globally, particularly in the EU, North America, and Asia-Pacific.
3. Pharmaceutical quality control — GMP requirements for sterility testing and environmental monitoring continue to expand, driven by regulatory expectations for biologic and advanced therapy manufacturing.

How This Fits the 2026 Medtech M&A Landscape

The Thermo Fisher–Astorg transaction is not an isolated deal. It is part of a broader wave of portfolio reshaping across the medtech and life sciences industries in 2025–2026.

The Divestiture Wave

According to Bain & Company's 2026 M&A Report, spin-offs and divestitures accounted for more than a third of strategic deal value in the first 11 months of 2025 — a noticeable increase from the previous five-year average. The report found that medtech deal value rose year over year and rebounded above pre-2023 levels, with the second half of 2025 particularly strong.

PwC's 2026 US Medtech Deals Outlook reinforced this theme: "Corporate portfolio reshaping will intensify as companies streamline operations to concentrate capital on differentiated technologies and high-growth procedural segments. Divestitures of non-core or subscale assets are likely to continue in 2026, creating a deeper pipeline of actionable opportunities for strategics and private equity buyers."

Major Portfolio Reshaping Transactions (2025–2026)

The Thermo Fisher–Astorg deal also illustrates a notable pattern: bidirectional deal flow between strategic buyers and private equity firms. An Astorg-led investor group sold Clario to Thermo Fisher for approximately $8.9 billion in March 2026; weeks later, Thermo Fisher sold the microbiology unit to Astorg for $1.075 billion. This kind of cross-flow — where the same firms act as both buyer and seller in different transactions — is becoming more common as strategics and PE firms each optimize for different portfolio objectives.

The transaction also arrives against a backdrop of slowing European private equity exit activity in Q1 2026, though deal pipelines are building toward a potential rebound. In this context, Astorg's willingness to commit over $1 billion to a diagnostics carve-out reflects sustained conviction in the standalone viability of specialty diagnostics platforms — and signals that PE sponsors continue to see attractive entry points in life sciences carve-outs even as the broader European PE market faces headwinds.

Comparison with Other Recent Divestitures

To understand the Thermo Fisher microbiology divestiture in context, it is useful to compare it with other major portfolio reshaping transactions:

Several observations emerge from this comparison:

• Private equity is playing an increasing role in absorbing divested assets that do not have a natural strategic acquirer. Astorg's acquisition of the microbiology unit — where the business will operate as a standalone platform — is a textbook example.
• Revenue multiples vary significantly based on growth profile, margin characteristics, and strategic fit. The 1.7x multiple for the Thermo Fisher microbiology business reflects its mature, steady-growth profile and the carve-out complexity involved.
• The seller's rationale is consistent across transactions. Whether it is Thermo Fisher, BD, Medtronic, or Solventum, the theme is the same: shed profitable but lower-growth or non-core businesses to concentrate capital on differentiated, high-growth categories.

The Microbiology Testing Market: Size and Growth Context

Understanding the divestiture requires understanding the market in which the microbiology business operates. The global microbiology testing market is substantial and growing:

Key market dynamics include:

• Clinical diagnostics accounts for approximately 31% of total microbiology testing revenue, driven by hospital demand for rapid pathogen identification and antimicrobial resistance monitoring.
• Pharmaceutical and biotech companies represent the largest end-user segment, reflecting strict cGMP requirements for sterility testing, environmental monitoring, and batch release testing.
• Food safety testing is growing as HACCP standards mandate pathogen screening at multiple production checkpoints globally.
• Asia-Pacific is the fastest-growing region (CAGR ~10.4%), driven by healthcare infrastructure expansion and pharmaceutical manufacturing growth.
• North America holds the largest regional market share (~35–39%), supported by the presence of leading manufacturers and advanced clinical laboratory infrastructure.

Against this backdrop, the Thermo Fisher microbiology unit's $645 million in revenue represents an estimated 8–10% share of the total global microbiology testing market, making it one of the largest pure-play microbiology platforms and a close competitor to bioMerieux.

What This Means for the Microbiology Market

The microbiology diagnostics market is at an interesting inflection point. The business being sold by Thermo Fisher competes primarily with bioMerieux, which held approximately 40% of the clinical microbiology market in 2024, along with Waters (which acquired microbiology products through its takeover of BD's biosciences business) and Danaher.

Potential Market Impact

1. A new independent competitor. The standalone microbiology company will be one of the largest pure-play microbiology diagnostics businesses globally. With $645 million in revenue and 13 global sites, it will have the scale to compete effectively — potentially with more strategic focus and investment flexibility than it had as a sub-unit within Thermo Fisher's vast portfolio.

2. Private equity-driven investment. Astorg's stated plan to "accelerate growth and enhance operational performance" suggests investment in R&D, commercial capabilities, and potential bolt-on acquisitions. This could make the standalone business a more aggressive competitor than it was under Thermo Fisher's ownership, where it competed for capital allocation against larger, faster-growing segments.

3. Competitive dynamics may intensify. If the standalone microbiology business invests more heavily in innovation and commercial reach, competitors like bioMerieux, Waters/BD, and Danaher may face a more focused challenger. Conversely, the transition period — establishing standalone operations, IT systems, regulatory registrations, and supply chain agreements — creates near-term execution risk.

4. Food safety and pharma QC as growth vectors. Astorg specifically called out food safety standards and pharmaceutical quality control as structural tailwinds. These end markets may receive more strategic attention and investment from the standalone entity than they did within Thermo Fisher's broader portfolio.

Implications for Diagnostics Companies

The Thermo Fisher–Astorg deal carries several lessons for diagnostics companies navigating the current M&A environment:

For Large-Cap Diagnostics Companies

• Expect continued portfolio pruning. PwC's 2026 outlook explicitly calls for intensifying corporate portfolio reshaping. Any diagnostics sub-unit that is not in the top two in its category, or that trails the corporate growth rate, is a potential divestiture candidate.
• Capital reallocation is a competitive weapon. The $1 billion+ in proceeds from this transaction gives Thermo Fisher additional firepower for acquisitions in higher-growth areas. Companies that do not actively manage their portfolios risk falling behind as competitors recycle capital more aggressively.
• Bidirectional deal flow is the new normal. Large-cap companies should be prepared to both acquire and divest, sometimes to the same counterparty. The Thermo Fisher–Astorg relationship — where Astorg sold Clario to Thermo Fisher and then bought the microbiology unit — exemplifies this dynamic.

For Mid-Cap and Specialty Diagnostics Companies

• Private equity is a viable alternative to strategic sale. Astorg's willingness to pay over $1 billion for a carve-out demonstrates that PE firms have the capital and operational capability to absorb complex, global diagnostics businesses.
• Carve-out readiness is a competitive advantage. Companies that maintain clean financial reporting, standalone regulatory registrations, and transferable IP will command higher valuations and smoother transactions.
• Independence can be energizing. A standalone microbiology platform backed by Astorg's healthcare expertise may be better positioned to innovate and compete than it was as a small piece of a $40 billion+ conglomerate.

For Industry Observers

• Track the management team. The success of the standalone microbiology business will depend heavily on the leadership team's ability to navigate the transition from corporate division to independent company. Astorg's track record suggests they will invest in management and governance.
• Watch for bolt-on acquisitions. Astorg's playbook — visible in its Solabia, CordenPharma, and Clario investments — typically involves organic growth supplemented by targeted acquisitions. The standalone microbiology business may pursue acquisitions in adjacent testing categories.
• Monitor the regulatory timeline. The deal is expected to close in H2 2026. Antitrust review should be straightforward given the absence of market overlap between Astorg and Thermo Fisher, but regulatory timelines can be unpredictable.

Key Takeaways

1. Thermo Fisher is selling its microbiology business to Astorg for approximately $1.075 billion, consisting of cash and a $50 million seller note. The deal was announced April 27, 2026, and is expected to close in H2 2026.

2. The microbiology unit generated $645 million in 2025 revenue with approximately 2,400 employees and 13 global manufacturing and R&D sites. It provides antimicrobial susceptibility testing (AST) and culture media solutions for clinical, pharmaceutical, and food safety markets.

3. The divestiture reflects Thermo Fisher's active portfolio management. CEO Marc Casper framed the transaction as generating capital for redeployment to higher-value opportunities. The deal will be dilutive to adjusted EPS by $0.15 in the first full year after close.

4. Astorg is building a dedicated healthcare platform. The pan-European PE firm has invested approximately EUR 8 billion in healthcare (~40% of its portfolio) and plans to operate the microbiology business as an independent, standalone company focused on accelerating growth.

5. The deal is part of a broader medtech portfolio reshaping trend. BD, Medtronic, J&J, and Solventum have all undertaken major divestitures in 2025–2026, driven by the same strategic logic: shed lower-growth or non-core assets to concentrate capital on differentiated, high-growth categories.

6. Bidirectional deal flow between strategics and PE is accelerating. An Astorg-led investor group sold Clario to Thermo Fisher for approximately $8.9 billion in March 2026; weeks later, Thermo Fisher sold the microbiology unit back to Astorg. This cross-flow reflects the complementary portfolio objectives of strategics (focus, scale) and PE firms (platform building, value creation).

7. The standalone microbiology business will be a significant new independent competitor. With $645 million in revenue, 2,400 employees, and 13 global sites — backed by a PE firm with deep healthcare expertise — the business has the scale and resources to compete aggressively in clinical, pharma QC, and food safety testing markets.

8. The medtech M&A environment favors disciplined execution. As PwC and Bain both noted in their 2026 outlooks, the current deal environment rewards precision — targeted, capability-building acquisitions and thoughtful divestitures — rather than scale for scale's sake.

9. Watch for Thermo Fisher's Q2 earnings call for more details on the financial impact and how the company plans to redeploy the approximately $1 billion in proceeds.

10. For diagnostics professionals, the message is clear. Portfolio optimization is not a one-time event — it is an ongoing strategic discipline. Companies that actively manage their portfolios, allocate capital to their highest-return opportunities, and maintain the operational flexibility to both acquire and divest will be best positioned in the evolving medtech landscape.